AbbVie Story Overview

ABBV -- USA Stock  

USD 89.95  4.45  4.71%

Macroaxis does not monitor all media channels or aggregates social signals for AbbVie. But even though we do not provide professional-grade financial sentiment analysis on AbbVie, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for AbbVie. Check also AbbVie Hype Analysis, AbbVie Correlation and AbbVie Performance.
Acquisition by Robert Alpern of tradable shares of AbbVie subject to Rule 16b-3
Filed transaction by Abbvie Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

AbbVie Inc insider trading alert for grant of stock equivalent units by Robert Alpern, the corporate stakeholder, on January 3, 2018. This event was filed by Abbvie Inc with SEC on 2018-01-03. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This media report from MacroaxisInsider distributed on January 3, 2018 was a factor to the next trading day price decrease.The overall trading delta against the next closing price was 0.57% . The overall trading delta when the story was published against the current closing price is 6.73% .

Similar stores for AbbVie

Stocks Highlights- AbbVie Inc. , Mitel Networks Corporation , HCA Healthcare, Inc ...news
Market Breaking Point Abbvie Holder Sarissa Capital Management LP Lowered Holding by 846000 as Shares Declined As Chevron ... Flecha 123 Microsoft Holder Mrj Capital Trimmed Position As Abbvie Stock Declined, Holder Anchor Capital ... The Cardinal Weekly Pharma giant on hunt for half-million square feet on Peninsula San Francisco Business TimesFull coverage
few days ago at http://hillaryhq.com 
Chicago Equity Partners Has Lifted Abbvie Position By 11.74 Million Harvest Capital Credit Has 0.75 ...
news
Hillary HQ Full coverage
over a week ago at http://www.equities.com 
AbbVie Inc. Dips 3.93 percent for July 11
Equities News
Equities.comFull coverage
over two weeks ago at www.macroaxis.com 
Sale by Laura Schumacher of 83893 shares of AbbVie
Macroaxis News
Filed transaction by Abbvie Inc officer. General open market or private sale of non-derivative or derivative security
over two weeks ago at http://finance.yahoo.com 
Should Value Investors Consider AbbVie Stock Now
news
Yahoo FinanceSkba Capital Management Decreased Its Holding in Abbvie as Valuation Declined Akamai Technologies Com ... MoneyMakingArticlesFull coverage
over three weeks ago at http://www.thestreetpoint.com 
Purchase by Glenn Tilton of 5400 shares of AbbVie
Thestreet News
Filed transaction by Abbvie Inc director. General open market or private purchase of non-derivative or derivative security
over three weeks ago at www.macroaxis.com 
AbbVie exotic insider transaction detected
Macroaxis News
Filed transaction by Abbvie Inc director. Unconventional Insider trading
over three weeks ago at http://stocknewsgazette.com 
Taking Tally Of KeyCorp , AbbVie Inc.
news
StockNewsGazetteAs Abbvie INC Com Stock Declined, Boston Advisors LLC Raised Stake KL DailyAs Abbvie INC Shares Declined, Horan Capital Advisors LLC Has Cut Holding by 3.40 Million Frisco FastballAbbVie Growth And Dividend In One Package Seeking AlphaFull coverage
over a month ago at http://www.streetinsider.com 
Form 424B2 JPMORGAN CHASE CO
Street Insider News
StreetInsider.comFull coverage
over a month ago at http://www.fool.com 
Humiras Sales Will Decline -- and Its Fantastic News for AbbVie
fool News
Motley FoolFull coverage
over a month ago at www.macroaxis.com 
Acquisition by Edward Rapp of 557 shares of AbbVie subject to Rule 16b-3
Macroaxis News
Filed transaction by Abbvie Inc director. Grant, award or other acquisition pursuant to Rule 16b-3
over two months ago at http://alphabetastock.com 
Investors are Unsure How to React AbbVie Inc
news
Alpha Beta StockFull coverage
over three months ago at www.macroaxis.com 
Sale by Richard Gonzalez of 34900 shares of AbbVie
Macroaxis News
Filed transaction by Abbvie Inc director. General open market or private sale of non-derivative or derivative security

Five Year Return

Five Year Return Comparative Analysis
  Five Year Return 
      AbbVie Comparables 
AbbVie is currently under evaluation in five year return category among related companies. Five Year Return is considered as one of the best measures to evaluate fund performance especially from the mid and long term prospective. It shows the total annualized return generated from holding a fund for the last 5 years and represents capital appreciation of fund investments including all dividends, losses, and capital gains distributions.

Peers

AbbVie Related Equities
GILD  0.09 %   
6.0%
BIIB  0.11 %   
7.0%
CELG  0.51 %   
34.0%
AMGN  0.54 %   
36.0%
BMY  0.6 %   
39.0%
LLY  0.67 %   
44.0%
MRK  0.68 %   
45.0%
PFE  0.8 %   
53.0%
AGN  1.4 %   
93.0%
ABT  1.5 %   
100.0%
Check also AbbVie Hype Analysis, AbbVie Correlation and AbbVie Performance. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">